. Author manuscript; available in PMC: 2017 Mar 1.

Published in final edited form as: Am J Prev Med. 2015 Nov 12;50(3):318–327. doi: 10.1016/j.amepre.2015.08.025

Table 4.

Adjusted Odds of HPV Vaccine Initiation by Sex of Sexual Partners (N=2,698)

Variable	Model 1	Model 2	Model 3

	OR (95% CI)	OR (95% CI)	OR (95% CI)
Sex of lifetime sexual partners
Only male (reference)	1.00	1.00	1.00
Both male and female	0.92 (0.67, 1.27)	0.99 (0.70, 1.39)	1.02 (0.73, 1.43)
Only female	0.96 (0.31, 3.02)	0.70 (0.25, 1.96)	0.99 (0.34, 2.84)
None	1.07 (0.78, 1.48)	0.65 (0.46, 0.92)	0.95 (0.67, 1.34)
Sex of past-year sexual partners
Only male (reference)	1.00	1.00	1.00
Both male and female	0.87 (0.53, 1.42)	0.81 (0.48, 1.37)	0.91 (0.51, 1.62)
Only female	0.17 (0.05, 0.59)	0.16 (0.05, 0.55)	0.28 (0.09, 0.90)
None	0.80 (0.59, 1.09)	0.69 (0.50, 0.94)	1.06 (0.77, 1.46)

Notes: Analyses were restricted to women who participated in Years 2-4 of the survey and reported having ever heard of the HPV vaccine. Sample size (N) refers to the observed sample. Model 1 is adjusted for age. Model 2 is further adjusted for race/ethnicity, nativity, religion in which raised, place of residence, relationship status, educational attainment, household poverty level, and employment status. Model 3 also includes health insurance status and receiving contraception in the past year. Boldface indicates statistical significance (p<0.05). All OR and 95% CI account for the complex survey design.